MX2017005277A - Extractos de cannabis y métodos de preparación y uso de la misma. - Google Patents

Extractos de cannabis y métodos de preparación y uso de la misma.

Info

Publication number
MX2017005277A
MX2017005277A MX2017005277A MX2017005277A MX2017005277A MX 2017005277 A MX2017005277 A MX 2017005277A MX 2017005277 A MX2017005277 A MX 2017005277A MX 2017005277 A MX2017005277 A MX 2017005277A MX 2017005277 A MX2017005277 A MX 2017005277A
Authority
MX
Mexico
Prior art keywords
preparing
methods
same
bds
cannabis extracts
Prior art date
Application number
MX2017005277A
Other languages
English (en)
Inventor
VERZURA Tony
Blackmon Earnie
Original Assignee
United Cannabis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54477280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005277(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by United Cannabis Corp filed Critical United Cannabis Corp
Publication of MX2017005277A publication Critical patent/MX2017005277A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con la extracción de componentes farmacéuticamente activos de materiales de planta, y de manera más particular a la preparación de una sustancia de fármaco botánico (BDS) para incorporación a un medicamento; también se relaciona con una BDS, para uso en formulaciones farmacéuticas; en particular se relaciona con BDS que comprenden cannabinoides obtenidos por medio de extracción desde cannabis.
MX2017005277A 2014-10-21 2015-10-21 Extractos de cannabis y métodos de preparación y uso de la misma. MX2017005277A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066795P 2014-10-21 2014-10-21
US201462068278P 2014-10-24 2014-10-24
PCT/US2015/056635 WO2016064987A1 (en) 2014-10-21 2015-10-21 Cannabis extracts and methods of preparing and using same

Publications (1)

Publication Number Publication Date
MX2017005277A true MX2017005277A (es) 2018-01-11

Family

ID=54477280

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005277A MX2017005277A (es) 2014-10-21 2015-10-21 Extractos de cannabis y métodos de preparación y uso de la misma.
MX2023007033A MX2023007033A (es) 2014-10-21 2017-04-21 Extractos de cannabis y metodos de preparacion y uso de la misma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007033A MX2023007033A (es) 2014-10-21 2017-04-21 Extractos de cannabis y metodos de preparacion y uso de la misma.

Country Status (15)

Country Link
US (4) US9730911B2 (es)
EP (1) EP3209312A1 (es)
JP (3) JP2017535539A (es)
KR (1) KR20170080608A (es)
CN (2) CN107205960A (es)
AU (1) AU2015335997B2 (es)
BR (2) BR122021018502B1 (es)
CA (2) CA2965493C (es)
CO (1) CO2017004974A2 (es)
EA (1) EA201790880A1 (es)
IL (1) IL251821B (es)
MX (2) MX2017005277A (es)
PH (1) PH12017500733A1 (es)
WO (1) WO2016064987A1 (es)
ZA (1) ZA201802715B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US11084770B2 (en) 2016-12-07 2021-08-10 Treehouse Biotech, Inc. Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
WO2013164824A1 (en) 2012-05-03 2013-11-07 Magdent Ltd. Bone enhancement device and method
US10319475B1 (en) 2014-06-13 2019-06-11 Enigami Systems, Inc. Method and apparatus for determining relationships between medications and symptoms
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
BR122021018502B1 (pt) * 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
AU2016226267A1 (en) 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US10960035B2 (en) 2015-04-01 2021-03-30 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) Erodium crassifolium L'Her plant extracts and uses thereof
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US20190062144A1 (en) * 2016-04-10 2019-02-28 Vireo Health LLC Cannabis Extract Dispensing System
GB2549277B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
EP3443496A1 (en) 2016-04-11 2019-02-20 Altopa, Inc. Secure portable, on-demand, microfluidic mixing and dispensing device
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
CA3022553C (en) * 2016-05-06 2023-02-21 Zeyead GHARIB The manufacturing methods, compositions, and medical applications of orally administered cannabis pharmaceuticals
US9717683B1 (en) 2016-06-29 2017-08-01 Ep Pharma, Llc Low-temperature inhalation administration of cannabinoid entities
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
AU2017293676A1 (en) 2016-07-03 2018-12-13 3277991 Nova Scotia Limited D/B/A Truro Herbal Co. Cannabis compositions and methods
AU2017307643B2 (en) * 2016-08-03 2019-07-25 Zelira Therapeutics Operations Pty Ltd Cannabis Composition
MX2019001286A (es) * 2016-08-03 2019-06-13 Zelda Therapeutics Operations Pty Ltd Composicion de cannabis.
WO2018023164A1 (en) * 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
IL248150B (en) 2016-09-29 2018-05-31 Garti Nissim A method for selective extraction of cannabinoid from plant origin
IL248149B (en) 2016-09-29 2020-03-31 Garti Nissim Formulations of dilutable cannabinoids and processes for their preparation
CA3077624A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US10525093B2 (en) * 2016-11-14 2020-01-07 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
WO2018113888A1 (en) * 2016-12-22 2018-06-28 Medcan Pharma A/S Liquid cannabinoid composition
USD802992S1 (en) 2017-01-16 2017-11-21 Altopa, Inc. Blend machine
US20190374502A1 (en) * 2017-02-09 2019-12-12 Bodhi Research & Development Inc. Cannabinoid-Containing Fatty Acid Formulations for Treating Disorders of the Nervous System
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
WO2018163164A1 (en) * 2017-03-05 2018-09-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for treating cancer
EP3600436A4 (en) * 2017-03-23 2020-12-30 Receptor Holdings, Inc. RAPID AND CONTROLLED ADMINISTRATION OF COMPOSITIONS WITH RESTORED SURROUNDING EFFECTS
BR112019020554A2 (pt) * 2017-03-30 2020-04-28 Ojai Energetics Pbc métodos e composições para melhorar as condições de saúde
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
CA2987979A1 (en) 2017-12-07 2019-06-07 Tresvertol Inc. Solvent-free thca extraction process
US20180343900A1 (en) * 2017-05-31 2018-12-06 Daniel Michael Leo Cannabis farming systems and methods
WO2018217803A2 (en) 2017-05-22 2018-11-29 Growblox Life Sciences L.L.C. Myrcene-containing complex mixtures targeting trpv1
WO2018222923A1 (en) 2017-05-31 2018-12-06 Phytecs, Inc. Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use
US10172897B2 (en) * 2017-06-06 2019-01-08 Cmg Partners, Inc. Enhanced smokable therapeutic cannabis product and method for making same
US10206888B2 (en) * 2017-06-06 2019-02-19 Cmg Partners, Inc. Cannabis-based therapeutic product for treatment of chronic pain
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
MX2019015315A (es) * 2017-06-19 2020-02-17 Zelda Therapeutics Operations Pty Ltd Composiciones y tratamientos para el trastorno del sueño.
US11318179B2 (en) * 2017-06-20 2022-05-03 Jessica Kado Topical formulation for binding to dermatological cannabinoid receptors
USD873068S1 (en) 2017-07-16 2020-01-21 Altopa, Inc. Blend device
US10272360B2 (en) 2017-08-05 2019-04-30 Priya Naturals, Inc. Phytochemical extraction system and methods to extract phytochemicals from plants including plants of the family Cannabaceae sensu stricto
US10597348B1 (en) * 2017-08-21 2020-03-24 Jeff Nordahl Infusing raw cannabinoids into food oil
CA3074173A1 (en) 2017-09-01 2019-03-07 Pureform Global, Inc. Synthetic cannabidiol compositions and methods of making the same
WO2019055587A1 (en) 2017-09-12 2019-03-21 Yakima Chief Hops, Llc CRYOGENIC CANNABIS LUPULIN TRICHOME OR TRICHOME TRICHOME GRANULES
AU2018101357B4 (en) * 2017-09-15 2022-03-17 Zelira Therapeutics Operations Pty Ltd Composition and method for treating autism
BR112020005918A2 (pt) 2017-09-28 2020-10-06 Zynerba Pharmaceuticals, Inc. tratamento da síndrome do x frágil com canabidiol
EP3691441A4 (en) * 2017-10-03 2020-11-25 Curo Medical Ltd. NEW PROCESS FOR MAKING CANNABIS AND PRODUCTS THEREOF
WO2019084679A1 (en) * 2017-10-30 2019-05-09 Whistler Technologies Corp. Terpene enrichment methods and systems
WO2019100168A1 (en) * 2017-11-27 2019-05-31 Enrico BOUCHARD Method of preparing a cannabis based terpene beverage and beverage thereof
US10941102B2 (en) * 2017-11-29 2021-03-09 Robert Henry Wohleb Aqueous leaching method to produce microcrystalline powder
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
WO2019153083A1 (en) * 2018-02-12 2019-08-15 CannTrust Inc. Extraction of cannabinoids from cannabis
WO2019165387A1 (en) 2018-02-23 2019-08-29 Spirtos Nicola Michael Cannabis based therapeutic and method of use
CA3096842A1 (en) * 2018-04-09 2019-10-17 Ellevet Sciences Hemp extract for treatment of pain in animals
US11260044B2 (en) * 2018-05-22 2022-03-01 Gbs Global Biopharma, Inc. TRPV1 activation-modulating complex mixtures of cannabinoids and/or terpenes
US11946016B2 (en) 2018-06-14 2024-04-02 Biosoma B.V. Process for the extraction of oil-soluble components from plant material
JP2021527132A (ja) * 2018-06-15 2021-10-11 キャンパル アニマル セラピューティクス リミテッド カンナビノイド組成物及びそれを使用した治療法
US10639340B2 (en) * 2018-06-18 2020-05-05 Eric Young Method of drying botanicals
US11591307B1 (en) * 2018-06-28 2023-02-28 Drive Foods Corp Method of processing cannabis plant matter
AU2018100924A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
AU2018100925A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Cannabinoid composition and method for treating PTSD and/or anxiety
AU2018100928A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for opioid sparing
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
CA3091719A1 (en) 2018-08-08 2020-02-13 Neptune Wellness Solutions Inc. Cold extraction method for cannabinoids and terpenes from cannabis by organic solvents
US11254633B2 (en) 2018-10-05 2022-02-22 Jonas Alcirdas Navickas Cannabis thin layer decarboxylation
US20200115663A1 (en) * 2018-10-16 2020-04-16 Golden Spice Liquors LLC Beverage compositions and methods of making and using the same
WO2020084413A1 (en) * 2018-10-23 2020-04-30 Radient Technologies Innovations Inc. Frozen biomass extraction
WO2020084427A1 (en) * 2018-10-23 2020-04-30 Radient Technologies Innovations Inc. Temperature control for active compound extraction
EP3876918A4 (en) * 2018-11-09 2022-08-10 Cronos Group Inc. LIQUID COMPOSITION FOR AN ELECTRONIC VAPOR DEVICE
EP3893858A1 (en) 2018-12-14 2021-10-20 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
US11243028B2 (en) 2018-12-14 2022-02-08 Fortunata, LLC Systems and methods of cryo-curing
BR102018076973A2 (pt) * 2018-12-21 2020-09-15 Entourage Participações S.A. Composição farmacêutica compreendendo extrato de cannabis, produto farmacêutico, processo de preparação da dita composição
US10888596B1 (en) 2018-12-28 2021-01-12 Cold Baked LLC Method of preparing Cannabis extracts
CN109862901A (zh) * 2019-01-22 2019-06-07 金湘范 一种提取生物活性成分的方法及由此获得的生物活性成分
US11078137B1 (en) * 2019-03-08 2021-08-03 Buddies IP Holding, Inc. Sustainable terpene extraction method
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
AU2020262269B2 (en) 2019-04-23 2024-03-28 Soma Oil Llc Cannabis processing systems and methods
US10993928B2 (en) 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
AU2020264426A1 (en) * 2019-05-01 2022-01-06 Cannadol Pharmaceuticals Compositions and methods for pain and anxiety relief
AU2020268218B2 (en) 2019-05-03 2022-09-08 Zyus Life Sciences Inc. Formulation for pain management
US11554098B2 (en) 2019-05-03 2023-01-17 HFL Partners, LLC Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing
US20200352191A1 (en) * 2019-05-06 2020-11-12 Karl Lonsbery Edible formulations and uses thereof
US11208393B2 (en) 2019-06-12 2021-12-28 Nectar Health Sciences Inc. Methods for extraction, processing, and purification of a selected family of target compounds from cannabis
US20220290069A1 (en) * 2019-08-20 2022-09-15 Treehouse Biosciences, Inc. Remediated oils
CN114761572A (zh) * 2019-08-27 2022-07-15 赫博利生物科技股份公司 大麻素浓缩物和分离物、获得该大麻素浓缩物和分离物的方法及其用途
US11253564B2 (en) 2019-09-06 2022-02-22 Perfect Herbal Blends, Inc. Optimizing volatile entourages in dry flowering plant mixtures
US20210068444A1 (en) * 2019-09-10 2021-03-11 California Amber Inc. Cannabinoid compositions with improved organoleptic and therapeutic properties, method of production, and use thereof
JP7326085B2 (ja) * 2019-09-19 2023-08-15 エステー株式会社 筋硬度低減剤
WO2021055886A1 (en) 2019-09-20 2021-03-25 Beaker Intellectual, Llc Isolation of cannabinoids from aqueous-extracted phytocannabinoid precipitates
US20210113490A1 (en) * 2019-10-21 2021-04-22 Avicanna Inc. Topical cannabinoid compositions for clear skin
US20210154596A1 (en) * 2019-11-21 2021-05-27 Jenny's Rose, LLC Cannabis Plant Extracts with Butane
CA3160750A1 (en) 2019-12-09 2021-06-17 Anthony Richard Gerardi Oral product comprising a cannabinoid
US20230047321A1 (en) * 2019-12-19 2023-02-16 Steven Rothstein Extracts enriched with polyphenolic compounds and related methods
US11351476B2 (en) 2020-01-07 2022-06-07 Agrify Corporation Method for chemical separation of cannabinoids
US20210213406A1 (en) * 2020-01-09 2021-07-15 Willamette Valley Alchemy Method and Apparatus for Curing Plant-Based Extracts
IL294598A (en) 2020-01-10 2022-09-01 Real Isolates Llc Methods for obtaining compounds from plant or fungal material, suitable compositions and their uses
WO2021231950A1 (en) * 2020-05-14 2021-11-18 Azdt Holdings, Llc Apparatus for cannabinol generation and methods of using the same
IT202000012448A1 (it) * 2020-05-26 2021-11-26 Sofar Spa Composizioni comprendenti un derivato della cannabis sativa e ceppi di batteri e loro uso terapeutico
IT202000012463A1 (it) * 2020-05-26 2021-11-26 Sofar Spa Composizioni comprendenti un derivato della cannabis sativa e ceppi di batteri e loro uso terapeutico
KR102388399B1 (ko) 2020-07-06 2022-04-20 안동시 대마 뿌리 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
KR20220005153A (ko) 2020-07-06 2022-01-13 안동시 대마 뿌리 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
KR102388396B1 (ko) 2020-07-06 2022-04-20 안동시 대마 줄기 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
KR20220005155A (ko) 2020-07-06 2022-01-13 안동시 대마 줄기 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
KR20220036035A (ko) 2020-09-15 2022-03-22 안동대학교 산학협력단 대마 잎 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
US11612627B2 (en) 2020-09-15 2023-03-28 Andong National University Industry-Academic Cooperation Foundation Method for preventing or treating thrombosis
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
KR102593702B1 (ko) * 2021-04-12 2023-10-25 농업회사법인 제이헴프코리아 주식회사 탈지대마씨앗 분말의 제조방법
GB202109021D0 (en) * 2021-06-23 2021-08-04 Ldn Pharma Ltd Treatment for autoimmune diseases
KR102346700B1 (ko) * 2021-07-30 2021-12-31 강원대학교산학협력단 대마로부터 고 함량의 칸나비디올을 대량생산하는 방법
US20230159483A1 (en) * 2021-11-24 2023-05-25 Dominick Monaco Cannabidiol extraction and conversion process
KR20230117982A (ko) 2022-02-03 2023-08-10 주식회사 네오켄바이오 칸나비노이드 추출물의 제조방법 및 칸나비노이드 추출물의 분석 방법
US11911427B2 (en) 2022-03-12 2024-02-27 Wilhelm Rumpf Extraction and infusion of active components from plant materials
CN114788480B (zh) * 2022-05-13 2023-02-03 黑龙江省农业科学院经济作物研究所 一种北方药用工业大麻花叶冻干收获方法
WO2023250274A1 (en) 2022-06-22 2023-12-28 Ilera Therapeutics Llc Enhanced capture and dissolution matrix for cannabinoids and methods of making the same
WO2024015780A1 (en) 2022-07-11 2024-01-18 Ilera Therapeutics Llc Zlt-007 and methods of treating diabetic neuropathy

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2304669A (en) 1940-08-16 1942-12-08 Adams Roger Isolation of cannabidiol
US6096740A (en) * 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US5434295A (en) 1994-02-07 1995-07-18 Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
US5773075A (en) 1996-12-13 1998-06-30 Kalamazoo Holdings, Inc. High temperature countercurrent solvent extraction of Capsicum solids
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
MXPA03007215A (es) 2001-02-14 2003-12-04 Gw Pharma Ltd Formulaciones farmaceuticas.
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20030050334A1 (en) 2001-04-30 2003-03-13 Murty Ram B. Process for extraction of Delta-9-Tetrahydrocannabinol and other related cannabinoids and preparation of specific strength marijuana cigarettes
GB2400319B (en) 2001-05-04 2005-06-08 Gw Pharma Ltd Cannabinoid-rich extracts
US20030017216A1 (en) 2001-07-23 2003-01-23 Schmidt Robert Gustav Isolation of herbal and cannabinoid medicinal extracts
US8034843B2 (en) 2002-02-01 2011-10-11 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
US20080057117A1 (en) 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
AU2003250372A1 (en) 2002-06-22 2004-01-06 Norton Healthcare Limited Pharmaceutical composition
DE10337458B4 (de) 2002-08-14 2010-10-14 Gw Pharma Ltd., Salisbury Verbesserungen bei der Extraktion von pharmazeutisch aktiven Komponenten aus Pflanzenmaterialien
US7344736B2 (en) 2002-08-14 2008-03-18 Gw Pharma Limited Extraction of pharmaceutically active components from plant materials
CA2454644C (en) 2002-08-14 2014-09-16 Gw Pharma Limited Cannabinoid liquid formulations for mucosal administration
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2393182B (en) 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
CA2503310A1 (en) 2005-04-08 2006-10-08 Antony Paul Hornby Method of activation of cannabis to render standardized preparations for therapeutic administration, other than smoking
US7968594B2 (en) 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2450741A (en) 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
CN102246992A (zh) * 2010-12-23 2011-11-23 东莞市德亨饮料食品有限公司 一种火麻仁杏仁露饮料及其制备方法
US20120264818A1 (en) * 2011-04-15 2012-10-18 Jon Newland Topical Compositions with Cannabis Extracts
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
DK2844243T3 (da) * 2012-05-03 2020-02-03 Echo Pharmaceuticals Bv Fremgangsmåde til fremstilling af et cannabisplante-isolat omfattende delta-9-tetrahydrocannabinol
WO2013169101A1 (en) * 2012-05-07 2013-11-14 Echo Pharmaceuticals B.V. Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
US20150313868A1 (en) 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
CA2902452C (en) 2013-02-28 2018-09-04 Full Spectrum Laboratories Limited Chemical engineering processes and apparatus for the synthesis of compounds
CA2904968A1 (en) * 2013-03-14 2014-10-02 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
CN105916492A (zh) 2013-10-31 2016-08-31 全谱实验室有限公司 萜烯和大麻素制剂
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
US20170340562A9 (en) 2014-05-12 2017-11-30 Hddc Holdings Llc Cannabinoid caffeinated drinks, powder, beans, and cannabinoid loose tea leaf
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
US20160039591A1 (en) 2014-07-22 2016-02-11 Craig E. Kinzer Packaging systems, devices, methods, and composition including cannabinoid unit dose forms
US20160081975A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Soft gel compositions and pre-gel concentrates
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
BR122021018502B1 (pt) * 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084770B2 (en) 2016-12-07 2021-08-10 Treehouse Biotech, Inc. Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol

Also Published As

Publication number Publication date
KR20170080608A (ko) 2017-07-10
CO2017004974A2 (es) 2017-11-10
WO2016064987A1 (en) 2016-04-28
BR112017008301A2 (pt) 2017-12-19
CN113509499A (zh) 2021-10-19
AU2015335997A1 (en) 2017-05-18
IL251821A0 (en) 2017-06-29
JP2023078465A (ja) 2023-06-06
EA201790880A1 (ru) 2017-08-31
ZA201802715B (en) 2019-09-25
US10555928B2 (en) 2020-02-11
US20170360745A1 (en) 2017-12-21
CA2965493C (en) 2021-12-07
IL251821B (en) 2021-02-28
BR112017008301B1 (pt) 2021-12-07
US9730911B2 (en) 2017-08-15
PH12017500733A1 (en) 2017-10-09
MX2023007033A (es) 2023-06-28
CA3135893A1 (en) 2016-04-28
BR122021018502B1 (pt) 2022-05-03
US20220218657A1 (en) 2022-07-14
EP3209312A1 (en) 2017-08-30
JP2017535539A (ja) 2017-11-30
US20160106705A1 (en) 2016-04-21
CA3135893C (en) 2023-11-14
JP2021042233A (ja) 2021-03-18
US20200215026A1 (en) 2020-07-09
AU2015335997B2 (en) 2020-10-01
CA2965493A1 (en) 2016-04-28
CN107205960A (zh) 2017-09-26
US11291650B2 (en) 2022-04-05

Similar Documents

Publication Publication Date Title
MX2023007033A (es) Extractos de cannabis y metodos de preparacion y uso de la misma.
MX2018013504A (es) Metodos de fabricacion, composiciones y aplicaciones medicas de productos farmaceuticos de cannabis administrables oralmente.
MX2018015699A (es) Formulaciones de cannabinoide.
FI3674298T3 (fi) Substituoituja indatsoleja, menetelmä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia valmisteita sekä niiden käyttö lääkkeiden valmistukseen
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
HRP20191265T8 (hr) Supstituirani 2-tiokso-imidazolidin-4-oni i njihovi spiro analozi, aktivni anti-kancerogeni sastojak, farmaceutska kompozicija, medicinski preparat, metoda za liječenje raka prostate
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
EP3167893A4 (en) Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases
EP3417867A4 (en) COMPOSITION WITH MEDICINAL EXTRACT AS ACTIVE AGENT FOR PREVENTING, DISABLING, OR TREATING STRESS OR DEPRESSIONS
MX2016010577A (es) Inhaladores de dosis medida presurizados y metodo de fabricacion.
WO2015126151A3 (ko) 신곡 추출물을 포함하는 상처 치료용 조성물
MY187299A (en) An extract of tinospora crispa and use as an antihypercholesterolemic agent
IN2015MU00907A (es)
UA90465U (uk) Спосіб реабілітації хворих на алкоголізм та наркозалежних, які часто хворіють на застудні захворювання